HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study.

AbstractOBJECTIVE:
Midodrine hydrochloride is a short-acting pressor agent that raises blood pressure in the upright position in patients with orthostatic hypotension. The US Food and Drug Administration's Subpart H approval, under which midodrine was initially approved, requires post-marketing studies to confirm midodrine's clinical benefit in this indication. The purpose of this study was to evaluate the clinical benefit of midodrine with regard to symptom response.
METHODS:
This was a double-blind, placebo-controlled, randomized, crossover, multicenter study (NCT01518946). Following screening, patients aged ≥18 years with severe symptomatic orthostatic hypotension and on a stable dose of midodrine for at least 3 months were randomized to treatment with either their previous midodrine dose or placebo on day 1 and the respective alternate treatment on day 2. The primary endpoint measured time to syncopal symptoms or near-syncope using a 45-min tilt-table test at 1 h post-dose.
RESULTS:
Thirty-three patients were screened for inclusion: 19 received at least one dose of midodrine and had at least one post-dose measurement of the primary endpoint. The least-squares mean time to syncopal symptoms or near-syncope after tilt-table initiation (mean ± standard error) was 1626.6 ± 186.8 s for midodrine and 1105.6 ± 186.8 s for placebo (difference, 521.0 s; 95 % confidence interval 124.2-971.7 s; p = 0.0131). There were 15 adverse events in 10 patients; all of these were mild or moderate in severity, with none considered by the investigators to be related to midodrine.
INTERPRETATION:
Midodrine is a well-tolerated and clinically effective treatment for symptomatic orthostatic hypotension.
AuthorsWilliam Smith, Hong Wan, David Much, Antoine G Robinson, Patrick Martin
JournalClinical autonomic research : official journal of the Clinical Autonomic Research Society (Clin Auton Res) Vol. 26 Issue 4 Pg. 269-77 (08 2016) ISSN: 1619-1560 [Electronic] Germany
PMID27372462 (Publication Type: Clinical Trial, Phase IV, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Vasoconstrictor Agents
  • Midodrine
Topics
  • Adolescent
  • Adult
  • Aged
  • Blood Pressure
  • Cross-Over Studies
  • Double-Blind Method
  • Female
  • Humans
  • Hypotension, Orthostatic (diagnosis, drug therapy)
  • Male
  • Middle Aged
  • Midodrine (adverse effects, therapeutic use)
  • Supine Position
  • Tilt-Table Test
  • Treatment Outcome
  • Vasoconstrictor Agents (adverse effects, therapeutic use)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: